97 related articles for article (PubMed ID: 3678785)
1. [Results of testing tumor resistance (in vitro--in vivo) in breast cancer].
Bartzke G; Rössler H; Seufert R; Möbus V; Kreienberg R
Geburtshilfe Frauenheilkd; 1987 Oct; 47(10):690-4. PubMed ID: 3678785
[TBL] [Abstract][Full Text] [Related]
2. [Drug sensitivity testing of gynecologic tumors using Volm's test and stem cell assay].
Eidtmann H; Jonat W; Maass H
Geburtshilfe Frauenheilkd; 1985 Jul; 45(7):477-81. PubMed ID: 4029587
[TBL] [Abstract][Full Text] [Related]
3. [Human tumor clonogenic assay in human breast cancer].
Kobayashi T; Kuraishi Y; Aiba K; Inoue K
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1566-72. PubMed ID: 3927846
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of the short-term incubation test for the therapy of metastatic breast cancer].
von Matthiessen H; Feldhammer B; Schürmann B; Koldovsky U
Dtsch Med Wochenschr; 1984 Sep; 109(36):1356-61. PubMed ID: 6468299
[TBL] [Abstract][Full Text] [Related]
5. In vitro clonogenic growth and metastatic potential of human operable breast cancer.
Nomura Y; Tashiro H; Hisamatsu K
Cancer Res; 1989 Oct; 49(19):5288-93. PubMed ID: 2766296
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
7. Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay.
Nio Y; Tamura K; Kan N; Inamoto T; Ohgaki K; Kodama H
Anticancer Res; 2000; 20(2B):1237-44. PubMed ID: 10810427
[TBL] [Abstract][Full Text] [Related]
8. The sensitivity testing of Wilms' tumors to cytostatic agents with an autoradiographic in vitro short-term test.
Willnow U
Neoplasma; 1984; 31(6):719-26. PubMed ID: 6097829
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of the cytostatic effect of epirubicin and mitoxantrone on native breast carcinoma cells using the ATP tumor chemosensitivity assay].
Kurbacher CM; Brenne U; Kurbacher JA; Mallmann P; Krebs D
Zentralbl Gynakol; 1996; 118(5):271-8. PubMed ID: 8701623
[TBL] [Abstract][Full Text] [Related]
10. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
14. In vitro clonogenicity in relation to kinetic and clinicopathological features of breast cancer.
Gioanni J; Farges MF; Duplay H; Hery M; Zanghellini E; Schneider M; Mazeau C; Namer M; Courdi A
Bull Cancer; 1988; 75(3):285-90. PubMed ID: 3370324
[TBL] [Abstract][Full Text] [Related]
15. [Results of in vitro chemosensitivity assays: human tumor clonogenic and scintillation assay].
Tanigawa N; Morimoto H; Akita T; Inoue H; Tanaka T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1176-84. PubMed ID: 3729439
[TBL] [Abstract][Full Text] [Related]
16. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma.
Abner AL; Collins L; Peiro G; Recht A; Come S; Shulman LN; Silver B; Nixon A; Harris JR; Schnitt SJ; Connolly JL
Cancer; 1998 Dec; 83(12):2502-8. PubMed ID: 9874455
[TBL] [Abstract][Full Text] [Related]
17. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay.
Schlag P; Schreml W
Cancer Res; 1982 Oct; 42(10):4086-9. PubMed ID: 7105006
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
20. [Choice of second-line chemotherapy for advanced breast cancer based on the chemosensitivity assay by in vitro colony assay].
Inoue K; Mukaiyama T; Yamazaki H; Horikoshi N; Ogawa M; Kobayashi T; Aiba K; Kuraishi Y
Gan To Kagaku Ryoho; 1986 Feb; 13(2):356-61. PubMed ID: 3080968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
